To investigate the effect of CNTN1 on primary neuroblastoma tumor growth and metastasis in vivo, we established CNTN1 knockout (crCNTN1) using a CRISPR-Cas9 system in both the non-MYCN-amplified SK-N-AS and the MYCN-amplified SK-N-DZ high-risk human neuroblastoma cell lines (Figure 3A,D). Here, MYCN is linked to neoplasm.